Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/23720226/ below:

Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program

Comparative Study

Affiliations

• ¹ Department of Research, Cancer Registry of Norway, Oslo, Norway; Oslo and Akershus University College of Applied Sciences, Oslo, Norway.

• PMID: 23720226
• PMCID: PMC4288930
• DOI: 10.1002/cncr.28174

Item in Clipboard

Comparative Study

Solveig Hofvind et al. Cancer. 2013.

• ¹ Department of Research, Cancer Registry of Norway, Oslo, Norway; Oslo and Akershus University College of Applied Sciences, Oslo, Norway.

• PMID: 23720226
• PMCID: PMC4288930
• DOI: 10.1002/cncr.28174

Item in Clipboard

Background: The Norwegian Breast Cancer Screening Program started in 1996. To the authors' knowledge, this is the first report using individual-based data on invitation and participation to analyze breast cancer mortality among screened and nonscreened women in the program.

Methods: Information on dates of invitation, attendance, breast cancer diagnosis, emigration, death, and cause of death was linked by using unique 11-digit personal identification numbers assigned all inhabitants of Norway at birth or immigration. In total, 699,628 women ages 50 to 69 years without prior a diagnosis of breast cancer were invited to the program from 1996 to 2009 and were followed for breast cancer through 2009 and death through 2010. Incidence-based breast cancer mortality rate ratios (MRRs) were compared between the screened and nonscreened cohorts using a Poisson regression model. The MRRs were adjusted for calendar period, attained age, years since inclusion in the cohorts, and self-selection bias.

Results: The crude breast cancer mortality rate was 20.7 per 100,000 women-years for the screened cohort compared with 39.7 per 100,000 women-years for the nonscreened cohort, resulting in an MRR of 0.52 (95% confidence interval, 0.47-0.59). The mortality reduction associated with attendance in the program was 43% (MRR, 0.57; 95% confidence interval, 0.51-0.64) after adjusting for calendar period, attained age, years after inclusion in the cohort, and self-selection bias.

Conclusions: After 15 years of follow-up, a 43% reduction in mortality was observed among women who attended the national mammographic screening program in Norway.

Keywords: Norway/epidemiology; breast neoplasms/mortality; breast neoplasms/prevention and control; breast neoplasms/radiography; female; mammography; mass screening.

Copyright © 2013 American Cancer Society.

PubMed Disclaimer

The number of women invited…

The number of women invited and screened in the Norwegian Breast Cancer Screening…

The number of women invited and screened in the Norwegian Breast Cancer Screening Program from 1996 to 2009, exclusions, and final study cohorts, including women-years, the number of breast cancer cases, and the number of breast cancer deaths from 1996 to 2010. DCIS indicates ductal carcinoma in situ.

Crude breast cancer mortality rates…

Crude breast cancer mortality rates are illustrated for the screened and nonscreened cohorts…

Crude breast cancer mortality rates are illustrated for the screened and nonscreened cohorts of women who were invited to the Norwegian Breast Cancer Screening Program according to the time since inclusion in the cohorts from 1996 to 2010.

Crude cumulative breast cancer mortality…

Crude cumulative breast cancer mortality rates are illustrated for the screened and nonscreened…

Crude cumulative breast cancer mortality rates are illustrated for the screened and nonscreened cohorts of women who were invited to the Norwegian Breast Cancer Screening Program according to the time since inclusion in the cohorts from 1996 to 2010.

• Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.

  Duffy S, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith R, Evans A, Blyuss O, Johns L, Ellis I, Sasieni P, Wale C, Myles J, Moss S. Duffy S, et al. Health Technol Assess. 2020 Oct;24(55):1-24. doi: 10.3310/hta24550. Health Technol Assess. 2020. PMID: 33141657 Free PMC article. Clinical Trial.

• Breast cancer mortality in Norway after the introduction of mammography screening.

  Olsen AH, Lynge E, Njor SH, Kumle M, Waaseth M, Braaten T, Lund E. Olsen AH, et al. Int J Cancer. 2013 Jan 1;132(1):208-14. doi: 10.1002/ijc.27609. Epub 2012 May 14. Int J Cancer. 2013. PMID: 22532175

• Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study.

  Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Kalager M, et al. Breast Cancer Res. 2009;11(4):R44. doi: 10.1186/bcr2331. Epub 2009 Jul 6. Breast Cancer Res. 2009. PMID: 19575807 Free PMC article. Clinical Trial.

• Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.

  Morrell S, Taylor R, Roder D, Robson B, Gregory M, Craig K. Morrell S, et al. Br J Cancer. 2017 Mar 14;116(6):828-839. doi: 10.1038/bjc.2017.6. Epub 2017 Feb 9. Br J Cancer. 2017. PMID: 28183141 Free PMC article.

• Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway.

  Kalager M, Løberg M, Bretthauer M, Adami HO. Kalager M, et al. Ann Oncol. 2014 Jun;25(6):1137-43. doi: 10.1093/annonc/mdu122. Epub 2014 Mar 24. Ann Oncol. 2014. PMID: 24669012

• Benefits and harms of mammography screening.

  Løberg M, Lousdal ML, Bretthauer M, Kalager M. Løberg M, et al. Breast Cancer Res. 2015 May 1;17(1):63. doi: 10.1186/s13058-015-0525-z. Breast Cancer Res. 2015. PMID: 25928287 Free PMC article. Review.

• Mammography screening in three Finnish residential areas: comprehensive population-based study of breast cancer incidence and incidence-based mortality 1976-2009.

  Parvinen I, Heinävaara S, Anttila A, Helenius H, Klemi P, Pylkkänen L. Parvinen I, et al. Br J Cancer. 2015 Mar 3;112(5):918-24. doi: 10.1038/bjc.2014.642. Epub 2015 Feb 17. Br J Cancer. 2015. PMID: 25688742 Free PMC article.

• The wisdom trial is based on faulty reasoning and has major design and execution problems.

  Kopans DB. Kopans DB. Breast Cancer Res Treat. 2021 Feb;185(3):549-556. doi: 10.1007/s10549-020-06020-7. Epub 2020 Nov 25. Breast Cancer Res Treat. 2021. PMID: 33237397 Review.

• Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.

  Chou CP, Huang NC, Jhuang SJ, Pan HB, Peng NJ, Cheng JT, Chen CF, Chen JJ, Chang TH. Chou CP, et al. PLoS One. 2014 Apr 3;9(4):e93934. doi: 10.1371/journal.pone.0093934. eCollection 2014. PLoS One. 2014. PMID: 24699941 Free PMC article.

• Misinformation and Facts about Breast Cancer Screening.

  Kopans DB. Kopans DB. Curr Oncol. 2022 Aug 9;29(8):5644-5654. doi: 10.3390/curroncol29080445. Curr Oncol. 2022. PMID: 36005183 Free PMC article.

1. 1. Vainio H, Bianchini F, editors. Breast Cancer Screening. Vol. 7. Lyon, France: IARC Press; 2002. Handbooks of Cancer Prevention.
2. 1. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography [serial online] Cochrane Database Syst Rev. 2011;(4):CD001877. - PubMed
3. 1. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–1786. - PubMed
4. 1. Broeders M, Moss SM, Nystrom L. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 2012;19(suppl 1):14–25. - PubMed
5. 1. Njor S, Nystrom L, Moss S, et al. et al. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(suppl 1):33–41. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3